CA Patent

CA3042062C — Methods of reducing the risk of cardiovascular events in a subject

Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2022-05-17 · 4y expired

What this patent protects

This disclosure pertains to use of about 3.7 g of eicosapentaenoic acid or dose-equivalent amount of a derivative thereof for daily administration to a subject on statin therapy for reducing a risk of cardiovascular death, myocardial infarction, stroke, coronary revascularization…

USPTO Abstract

This disclosure pertains to use of about 3.7 g of eicosapentaenoic acid or dose-equivalent amount of a derivative thereof for daily administration to a subject on statin therapy for reducing a risk of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and/or unstable angina, wherein the subject has diabetes and at least one risk factor for cardiovascular disease without an established cardiovascular disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA3042062C
Jurisdiction
CA
Classification
—
Expires
2022-05-17
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.